Zurcher Kantonalbank Zurich Cantonalbank Has $46.33 Million Holdings in Amgen, Inc. (AMGN)
Zurcher Kantonalbank Zurich Cantonalbank decreased its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 12.9% during the fourth quarter, HoldingsChannel.com reports. The fund owned 266,416 shares of the medical research company’s stock after selling 39,567 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Amgen were worth $46,330,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also modified their holdings of the company. Baker Ellis Asset Management LLC bought a new stake in Amgen during the 3rd quarter valued at $108,000. Jackson Grant Investment Advisers Inc. raised its holdings in Amgen by 0.8% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock valued at $110,000 after acquiring an additional 5 shares during the period. Phocas Financial Corp. bought a new stake in Amgen during the 2nd quarter valued at $110,000. Omnia Family Wealth LLC raised its holdings in Amgen by 25.3% during the 2nd quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock valued at $125,000 after acquiring an additional 147 shares during the period. Finally, Salem Investment Counselors Inc. raised its holdings in Amgen by 4.7% during the 2nd quarter. Salem Investment Counselors Inc. now owns 809 shares of the medical research company’s stock valued at $139,000 after acquiring an additional 36 shares during the period. 78.61% of the stock is currently owned by institutional investors and hedge funds.
Amgen, Inc. (AMGN) opened at $191.10 on Friday. Amgen, Inc. has a 1 year low of $152.16 and a 1 year high of $201.23. The stock has a market cap of $137,699.41, a price-to-earnings ratio of 15.19, a P/E/G ratio of 2.35 and a beta of 1.37. The company has a debt-to-equity ratio of 1.35, a current ratio of 5.49 and a quick ratio of 5.17.
Amgen announced that its board has initiated a stock repurchase plan on Thursday, February 1st that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the medical research company to repurchase shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s leadership believes its stock is undervalued.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be given a $1.32 dividend. The ex-dividend date of this dividend is Wednesday, May 16th. This represents a $5.28 annualized dividend and a yield of 2.76%. Amgen’s dividend payout ratio (DPR) is presently 205.45%.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $174.18, for a total transaction of $265,624.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 4,575 shares of company stock valued at $818,361 over the last quarter. 0.19% of the stock is owned by company insiders.
AMGN has been the topic of a number of analyst reports. BidaskClub raised shares of Amgen from a “strong sell” rating to a “sell” rating in a report on Saturday, December 2nd. Morgan Stanley decreased their price target on shares of Amgen from $204.00 to $196.00 and set an “overweight” rating on the stock in a report on Friday, February 2nd. Vetr raised shares of Amgen from a “sell” rating to a “hold” rating and set a $181.60 price target on the stock in a report on Tuesday, February 27th. Oppenheimer reaffirmed a “buy” rating and issued a $205.00 price target on shares of Amgen in a report on Tuesday, January 30th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating on shares of Amgen in a report on Tuesday, January 2nd. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and eleven have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $191.72.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.